Economic Times•2 Jun 2026
US stocks: Fulcrum shares plummet over 50% after scrapping lead sickle-cell drug on FDA concernsUS stocks saw a significant drop as Fulcrum shares plummeted over 50% after the company scrapped its lead sickle-cell drug, pociredir, due to FDA concerns. The oral drug was being tested to treat sickle-cell disease, an inherited blood disorder. This development has impacted investor sentiment in the pharmaceutical sector.